Vipragen Biosciences

What Vipragen Biosciences does

Vipragen Biosciences is a preclinical Contract Research Organization (CRO) headquartered in Mysuru, Karnataka, India. Founded in 2012 and operating with 11-50 employees, the company provides outsourced preclinical research and development services to pharmaceutical and biotechnology companies, including drug development support, regulatory compliance testing, and safety study execution. Its service offering is delivered through direct B2B sales engagement with pharma, biotech, and increasingly adjacent industry clients, with pricing structured as custom professional-services quotes per project scope.

The company's technology footprint is that of a traditional preclinical CRO — specialized laboratory infrastructure, regulatory-compliant study protocols, and access to India's scientific talent pool in Mysuru rather than a proprietary software or AI platform. No patents, software products, APIs, or named technology platforms are disclosed; the product surface is the contracted research engagement itself. Vipragen has no disclosed customer logos and serves primarily small and mid-sized pharma/biotech buyers as well as nutraceutical, agrochemical, and medical device clients.

Vipragen's revenue model is professional-services based, monetizing through project-by-project research contracts. The company is venture-backed (currently post-second-round) with KITVEN, the Karnataka government venture fund, and Conscience Multi Family Office LLP as its disclosed investors from an August 2023 round. Founder, Chairman, and CEO Chandrashekaran Siddamadappa leads the company. Geographic scope is domestic India, with no disclosed offshore or international revenue.

Name

Vipragen Biosciences

Legal name

Vipragen Biosciences

Website

https://vipragen.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Vipragen Biosciences is a Mysuru, India-based preclinical Contract Research Organization that provides outsourced drug development, regulatory compliance testing, and safety studies to pharmaceutical, biotech, nutraceutical, agrochemical, and medical device companies.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Regulatory Consulting & Compliance Program Management (FDA/USDA/EFSA) (AFALADAC)

Keywords

• Preclinical CRO services
• Drug development research
• Contract research organization
• Pharmaceutical research services
• Biotech research services

Headquarters

HQ city

Mysore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Preclinical CRO Services: Contract research organization providing preclinical research and development services to pharmaceutical, biotech, and related companies. Revenue generated through service contracts for research studies, drug development support, and regulatory compliance testing.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Vipragen Biosciences is a preclinical Contract Research Organization (CRO) that provides drug development research, safety profiling, and regulatory compliance testing services to pharmaceutical and biotech companies. The company conducts outsourced preclinical research studies and prepares drug candidates for regulatory submissions. It is expanding its service capabilities into adjacent sectors including Nutraceuticals, Agrochemicals, and Medical Devices.

Product overview

Vipragen Biosciences is a preclinical Contract Research Organization (CRO) based in Mysuru, India. The company operates in the bioscience sector and is expanding its operations into adjacent sectors including Nutraceuticals, Agrochemicals, and Medical Devices. No specific named products, modules, or sub-brands are identified in the available source data.

Differentiator

Problem solved

Functional benefit

Products and services

• Preclinical CRO Research Services

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Aragen Life Sciences (formerly GVK Biosciences): Large Indian preclinical CRO offering discovery, DMPK, safety assessment, and CMC services to global pharma. Direct comparable to Vipragen's preclinical CRO offering, though materially larger in scale; represents the scale-up trajectory and competitive benchmark.
• Sai Life Sciences: India-based integrated CRO/CDMO offering discovery, preclinical, and CMC services to global pharma and biotech. Comparable in service mix (discovery/preclinical CRO) and in serving Indian and global pharma customers from a Hyderabad base.
• Suven Life Sciences: India-based CRO/CDMO with discovery, preclinical, and contract manufacturing capabilities. Comparable in offering preclinical CRO services to pharma clients, with overlap in nutraceuticals and adjacent sectors as Vipragen is building.
• Anthem Biosciences: India-based preclinical and discovery CRO headquartered in Bengaluru, offering drug discovery, DMPK, toxicology, and formulation services. Highly comparable to Vipragen as a specialized preclinical CRO of similar size serving pharma and biotech globally from a Karnataka/South India base.
• Vanta Bioscience: Smaller India-based preclinical CRO offering toxicology, safety assessment, and regulatory studies. Closely comparable in size, service scope (preclinical/tox CRO), and target customer profile to Vipragen.
• Eurofins Advinus: India-based preclinical CRO specializing in toxicology, DMPK, and safety sciences, now part of Eurofins. Directly comparable in preclinical service lines, and the Eurofins acquisition illustrates the consolidation trajectory available to Indian preclinical CROs at Vipragen's scale.
• Jubilant Biosys: India-based drug discovery and preclinical CRO offering integrated services in medicinal chemistry, DMPK, and toxicology. Closely comparable in preclinical CRO service lines and Indian/global pharma customer base.

Broad incumbents

• Piramal Pharma Solutions: Large Indian CDMO/CRO offering drug discovery through commercial manufacturing. Adjacent incumbent to Vipragen's preclinical CRO offering; serves similar Indian/global pharma customers but with much broader scope.
• Syngene International: India's largest listed CRO offering discovery, preclinical, clinical, and manufacturing services. Sets the pricing/service benchmark for India-based preclinical CROs and represents the gold-standard incumbent Vipragen competes against for global pharma mandates.

Regional players

• Dabur Research Foundation: India-based preclinical research CRO with focus on safety/toxicology, biologicals, and natural products. Comparable as a domestic India preclinical CRO with overlap in the nutraceutical/ayurvedic R&D segment Vipragen is targeting.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/biosciences-vipragen

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vipragen Biosciences